Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, announced publication of abstracts on neratinib for the
American Association for Cancer Research (AACR) Annual Meeting
2017. The AACR Annual Meeting will be held at the Walter E.
Washington Convention Center in Washington, D.C. from April 1 to
April 5.
Full abstracts of the following presentations are available
online at www.aacr.org:
Apr. 4, 2017, 1:00 - 5:00 p.m. EDT – Abstract 4818
(Poster): Neratinib/fulvestrant but not fulvestrant alone maintain
complete tumor responses after treatment with trastuzumab +
paclitaxel of mice bearing ER+/HER2+ xenografts.L.J. Schwarz et al,
Vanderbilt University Medical Center.
April 4, 2017, 1:00 - 5:00 p.m. EDT – Abstract 4157
(Poster): Co-blockade of mTORC1, ERBB and estrogen receptor
signaling pathways in endocrine resistant breast cancer: combating
tumour plasticity.R. Ribas et al, Institute of Cancer Research.
April 4, 2017, 1:00 - 5:00 p.m. EDT – Abstract 4038
(Poster): Exploring optimal targeted combination therapies with
neratinib for HER2+ breast cancer.M. Zhao et al, MD Anderson Cancer
Center.
April 5, 2017, 8:00 - 12:00 p.m. EDT – Abstract 5167
(Poster): Stem-like colorectal cancer cell lines show response to
the ERK1/2 inhibitor, SCH772984, alone and in combination with
neratinib while the combination of MEK-162 and neratinib work to
decrease tumor growth in inflammatory colorectal cancer subtypes.R.
Pal et al, NSABP.
April 5, 2017, 8:00 - 12:00 p.m. EDT – Abstract 5684
(Poster): NSABP FC-7 Correlative Study: HER2 amplification in
circulating cell-free DNA (cfDNA) in metastatic colorectal cancer
(mCRC) resistant to anti-EGFR therapy.S. Rim Kim et al, NSABP.
Full abstracts of the following presentations are expected to
be available online March 31, 2017, after 4:00 p.m. EDT:
April 2, 2017, 12:45 - 3:00 p.m. EDT – Abstract CT001
(Oral, Clinical Trials Plenary Session): Neratinib in HER2 or HER3
mutant solid tumors: SUMMIT, a global, multi-histology, open-label,
phase 2 ‘basket’ study.D. Hyman et al, Memorial Sloan Kettering
Cancer Center.
April 2, 2017, 3:00 - 5:00 p.m. EDT – Abstract CT011
(Oral, Minisymposium): Circulating tumor DNA (ctDNA) sequencing for
HER2 mutation (HER2mut) screening and response monitoring to
neratinib in metastatic breast cancer (MBC).C. Ma et al, Washington
University School of Medicine.
April 2, 2017, 3:00 - 5:00 p.m. EDT – Abstract CT013
(Oral, Minisymposium): NSABP FB-10: Phase Ib dose-escalation trial
evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in
women with metastatic HER2+ breast cancer (MBC).J. Abraham et al,
NSABP.
April 3, 2017, 10:30 a.m. – 12:45 p.m. EDT – Abstract
LB103 (Oral, Major Symposium): Landscape of Somatic ERBB2 Mutations
- Findings from AACR GENIE and Comparison to Ongoing ERBB2 Mutant
Basket Study.A. Schram et al, Memorial Sloan Kettering Cancer
Center.
April 4, 2017, 1:00 - 5:00 p.m. EDT – Abstract CT128
(Poster): Effects of adding budesonide or colestipol to loperamide
prophylaxis on neratinib-associated diarrhea in patients (pts) with
HER2+ early-stage breast cancer (eBC): the CONTROL trial.E. Ibrahim
et al, Beaver Medical Group LP.
About Puma Biotechnology:
Puma Biotechnology, Inc. is a biopharmaceutical company with a
focus on the development and commercialization of innovative
products to enhance cancer care. The Company in-licenses the global
development and commercialization rights to three drug
candidates—PB272 (neratinib (oral)), PB272 (neratinib
(intravenous)) and PB357. Neratinib is a potent irreversible
tyrosine kinase inhibitor that blocks signal transduction through
the epidermal growth factor receptors, HER1, HER2 and HER4.
Currently, the Company is primarily focused on the development of
the oral version of neratinib, and its most advanced drug
candidates are directed at the treatment of HER2-positive breast
cancer. The Company believes that neratinib has clinical
application in the treatment of several other cancers as well,
including non-small cell lung cancer and other tumor types that
over-express or have a mutation in HER2.
Further information about Puma Biotechnology may be found
at www.pumabiotechnology.com.
Forward-Looking Statements:
This press release contains forward-looking statements that
involve risks and uncertainties that could cause the Company's
actual results to differ materially from the anticipated results
and expectations expressed in these forward-looking statements.
These statements are based on current expectations, forecasts and
assumptions, and actual outcomes and results could differ
materially from these statements due to a number of factors, which
include, but are not limited to, the risk factors disclosed in the
periodic reports filed by the Company with the Securities and
Exchange Commission from time to time. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. The Company assumes no obligation
to update these forward-looking statements, except as required by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170301006637/en/
Puma Biotechnology, Inc.Alan H. Auerbach or Mariann Ohanesian,
+1
424-248-6500info@pumabiotechnology.comir@pumabiotechnology.comorRusso
PartnersDavid Schull or Darren Chia, +1
212-845-4242david.schull@russopartnersllc.comdarren.chia@russopartnersllc.com
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Apr 2024 to May 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From May 2023 to May 2024